Pilot Study of Reduced Venetoclax Exposure

This study tests whether people with acute myeloid leukemia (AML) — a blood cancer — who have responded well to initial treatment can do just as well with a lower dose of a drug called venetoclax during ongoing therapy. The goal is to reduce side effects while keeping the cancer in remission. **You may be eligible if...** - You have been diagnosed with AML - You were treated with a combination of azacitidine or decitabine plus venetoclax - Your AML has gone into remission (less than 5% cancer cells in bone marrow) - You achieved remission within 3 treatment cycles - You are able to take oral medications and follow the study schedule **You may NOT be eligible if...** - You have not yet achieved remission - You are unable to take oral medications - You are not willing to follow the study protocol Talk to your doctor to see if this trial is right for you.